FRANCOIS CLARET

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Phosphatases: the new brakes for cancer development?
    Qingxiu Zhang
    Department of Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Enzyme Res 2012:659649. 2012
  2. pmc Trastuzumab: updated mechanisms of action and resistance in breast cancer
    Thuy Vu
    Department of Systems Biology, The University of Texas MD Anderson Cancer Center Houston, TX, USA
    Front Oncol 2:62. 2012
  3. pmc Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways
    Y Pan
    Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncogene 32:2756-66. 2013
  4. pmc Stat3 inhibitor Stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma
    Yunbao Pan
    Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    PLoS ONE 8:e54565. 2013
  5. pmc Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia
    Fuling Zhou
    Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Leukoc Biol 94:423-9. 2013
  6. pmc Curcumin analogue T83 exhibits potent antitumor activity and induces radiosensitivity through inactivation of Jab1 in nasopharyngeal carcinoma
    Yunbao Pan
    Department of Pathophysiology, Zhongshan School of Medicine, Sun Yat Sen University, Guangzhou, Guangdong 510080, People s Republic of China
    BMC Cancer 13:323. 2013
  7. pmc JAB1/CSN5: a new player in cell cycle control and cancer
    Terry J Shackleford
    Department of Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Cell Div 5:26. 2010
  8. pmc Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells
    Terry J Shackleford
    Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Breast Cancer Res 13:R65. 2011

Research Grants

Collaborators

Detail Information

Publications8

  1. pmc Phosphatases: the new brakes for cancer development?
    Qingxiu Zhang
    Department of Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Enzyme Res 2012:659649. 2012
    ....
  2. pmc Trastuzumab: updated mechanisms of action and resistance in breast cancer
    Thuy Vu
    Department of Systems Biology, The University of Texas MD Anderson Cancer Center Houston, TX, USA
    Front Oncol 2:62. 2012
    ..In line with that, our review highlights the well-accepted mechanisms of action and resistance to the therapy and discusses the progress that has been made toward successfully overcoming this resistance...
  3. pmc Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways
    Y Pan
    Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncogene 32:2756-66. 2013
    ..Therefore, Jab1 is a novel biomarker for predicting the outcome of patients with NPC who are treated with DNA-damaging agents...
  4. pmc Stat3 inhibitor Stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma
    Yunbao Pan
    Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    PLoS ONE 8:e54565. 2013
    ..Taken together, Stattic inhibit Stat3 and display antitumor effect in NPC, and enhanced chemosensitivity and radiosensitivity in NPC. Therefore, our findings provide the base for more rational approaches to treat NPC in the clinic...
  5. pmc Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia
    Fuling Zhou
    Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Leukoc Biol 94:423-9. 2013
    ..In this review, we summarize the recent findings that support a role for ROS in the pathogenesis of AML and outline innovative approaches in the implementation of redox therapies for myeloid malignancies. ..
  6. pmc Curcumin analogue T83 exhibits potent antitumor activity and induces radiosensitivity through inactivation of Jab1 in nasopharyngeal carcinoma
    Yunbao Pan
    Department of Pathophysiology, Zhongshan School of Medicine, Sun Yat Sen University, Guangzhou, Guangdong 510080, People s Republic of China
    BMC Cancer 13:323. 2013
    ..In this study, we explored the antitumor effect of a curcumin analogue T83 in NPC, and found T83 exhibits antitumor activity and induces radiosensitivity through inactivation of Jab1 in NPC...
  7. pmc JAB1/CSN5: a new player in cell cycle control and cancer
    Terry J Shackleford
    Department of Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Cell Div 5:26. 2010
    ..Further, we also discuss the regulation of Jab1/CSN5 in cancers and its potential as a therapeutic target...
  8. pmc Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells
    Terry J Shackleford
    Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Breast Cancer Res 13:R65. 2011
    ..The mechanism of Jab1 gene expression and its deregulation in cancer cells remains to be identified. We therefore investigated the transcriptional regulatory mechanisms of Jab1 expression in human breast carcinoma cells...

Research Grants10

  1. Targeting JAB1 Oncogenic Function in Breast Cancer
    FRANCOIS CLARET; Fiscal Year: 2007
    ..Upstream targets regulating JAB1 expression may be identified for use in future therapeutic paradigms. ..
  2. Molecular Mode of Action of JAB-1 in Cell Proliferation
    FRANCOIS CLARET; Fiscal Year: 2002
    ..Using JAB1 to re-establish a G1 checkpoint in tumor cells to block proliferation could represent a powerful therapeutic tool. ..
  3. Validation of new biomarker for human cancers
    FRANCOIS CLARET; Fiscal Year: 2006
    ..Development of new prognosis/diagnostic markers for breast cancer and lymphoma would be invaluable. ..
  4. Molecular Mode of Action of JAB-1 in Cell Proliferation
    FRANCOIS CLARET; Fiscal Year: 2005
    ..Using JAB1 to re-establish a G1 checkpoint in tumor cells to block proliferation could represent a powerful therapeutic tool. ..
  5. Molecular Mode of Action of JAB-1 in Cell Proliferation
    FRANCOIS CLARET; Fiscal Year: 2004
    ..Using JAB1 to re-establish a G1 checkpoint in tumor cells to block proliferation could represent a powerful therapeutic tool. ..
  6. Molecular Mode of Action of JAB-1 in Cell Proliferation
    FRANCOIS CLARET; Fiscal Year: 2006
    ..Using JAB1 to re-establish a G1 checkpoint in tumor cells to block proliferation could represent a powerful therapeutic tool. ..
  7. Molecular Mode of Action of JAB-1 in Cell Proliferation
    FRANCOIS CLARET; Fiscal Year: 2003
    ..Using JAB1 to re-establish a G1 checkpoint in tumor cells to block proliferation could represent a powerful therapeutic tool. ..
  8. Targeting JAB1 Oncogenic Function in Breast Cancer
    FRANCOIS CLARET; Fiscal Year: 2009
    ..Upstream targets regulating JAB1 expression may be identified for use in future therapeutic paradigms. ..
  9. Targeting JAB1 Oncogenic Function in Breast Cancer
    Francois X Claret; Fiscal Year: 2010
    ..Upstream targets regulating JAB1 expression may be identified for use in future therapeutic paradigms. ..